Eiger to Discontinue Phase 3 LIMT-2 Trial of Peginterferon Lambda in Patients with Chronic Hepatitis Delta

Stock Information for Eiger BioPharmaceuticals Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Eiger BioPharmaceuticals Inc.

Eiger BioPharmaceuticals Files for Voluntary Chapter 11 Protection
Eiger and Partner, AnGes, Receive Approval for Zokinvy® (lonafarnib) for Hutchinson- Gilford Progeria Syndrome and Processing-Deficient Progeroid Laminopathies in Japan
Eiger BioPharmaceuticals, Inc. Announces 1-for-30 Reverse Stock Split
Eiger BioPharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update
Eiger BioPharmaceuticals to Present at H.C. Wainwright 25th Annual Global Investment Conference
Eiger BioPharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update
Eiger BioPharmaceuticals to Focus on Metabolic Diseases with Avexitide; David Apelian Takes Helm as CEO
Eiger BioPharmaceuticals to Host Business Update Call Tomorrow

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.